Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 37.77 USD -0.16% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

SUPN Price Targets Summary
Supernus Pharmaceuticals Inc

Wall Street analysts forecast SUPN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUPN is 40.04 USD with a low forecast of 36.36 USD and a high forecast of 45.15 USD.

Lowest
Price Target
36.36 USD
4% Downside
Average
Price Target
40.04 USD
6% Upside
Highest
Price Target
45.15 USD
20% Upside

SUPN Last Price Targets
Supernus Pharmaceuticals Inc

The latest public price target was made on Sep 11, 2024 by David Amsellem from Piper Sandler , who expects SUPN stock to drop by 5% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
David Amsellem
Piper Sandler
36 USD
Downside 5%
2 months ago
Sep 11, 2024
Piper downgrades Supernus to Neutral on slower Qelbree growth
TheFly
David Amsellem
Piper Sandler
41 USD
Upside 9%
5 months ago
May 24, 2024
Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN)
StreetInsider
Annabel Samimy
Stifel Nicolaus
38 USD
Upside 1%
7 months ago
Apr 8, 2024
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
StreetInsider
Irene Buhalo
Jefferies
40 USD
Upside 6%
7 months ago
Apr 8, 2024
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
StreetInsider
David Amsellem
Piper Sandler
Price Target 36 USD
Upside/Downside 5%
View Source
David Amsellem
Piper Sandler
Price Target 41 USD
Upside/Downside 9%
View Source
Annabel Samimy
Stifel Nicolaus
Price Target 38 USD
Upside/Downside 1%
View Source
Irene Buhalo
Jefferies
Price Target 40 USD
Upside/Downside 6%
View Source
Supernus Pharmaceuticals Inc Competitors:
Price Targets
688321
Shenzhen Chipscreen Biosciences Co Ltd
34% Upside
AUROPHARMA
Aurobindo Pharma Ltd
27% Upside
DMP
Dermapharm Holding SE
62% Upside
JUBLPHARMA
Jubilant Pharmova Ltd
6% Upside
PHO
Photocure ASA
88% Upside
APLLTD
Alembic Pharmaceuticals Ltd
13% Upside
4547
Kissei Pharmaceutical Co Ltd
5% Upside
UCB
Ucb SA
8% Downside

Revenue
Forecast

Revenue Estimate
Supernus Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Supernus Pharmaceuticals Inc's revenue is 19%. The projected CAGR for the next 3 years is 4%.

19%
Past Growth
4%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Supernus Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Supernus Pharmaceuticals Inc's operating income is -4%. The projected CAGR for the next 3 years is 117%.

-4%
Past Growth
117%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Supernus Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Supernus Pharmaceuticals Inc's net income is -26%. The projected CAGR for the next 3 years is 364%.

-26%
Past Growth
364%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SUPN's stock price target?
Price Target
40.04 USD

According to Wall Street analysts, the average 1-year price target for SUPN is 40.04 USD with a low forecast of 36.36 USD and a high forecast of 45.15 USD.

What is Supernus Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Supernus Pharmaceuticals Inc's revenue is 19%. The projected CAGR for the next 3 years is 4%.

What is Supernus Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
117%

For the last 8 years the compound annual growth rate for Supernus Pharmaceuticals Inc's operating income is -4%. The projected CAGR for the next 3 years is 117%.

What is Supernus Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
364%

For the last 8 years the compound annual growth rate for Supernus Pharmaceuticals Inc's net income is -26%. The projected CAGR for the next 3 years is 364%.

Back to Top